Overview

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Status:
RECRUITING

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.

Phase:

PHASE2

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Paclitaxel
S 1 (combination)